Emergent BioSolutions Inc.

Public Company, Headquarters Location
2273 Research Blvd, Ste. 400, Rockville, MD 20850-3285, United States
(301)795-1800, (301)795-1899 fax, http://www.emergentbiosolutions.com

Primary SIC: Pharmaceutical Preparations, Primary NAICS: Pharmaceutical Preparation Manufacturing
Description: Emergent Biosolutions Inc. was incorporated as BioPort Corporation in Michigan in May 1998. In June 2004, the company completed a corporate reorganization in which BioPort became a wholly-owned subsidiary of Emergent BioSolutions Inc., a Delaware corporation formed in December 2003. BioPort was subsequently renamed Emergent BioDefense Operations Lansing Inc. Headquartered in Rockville, Md., Emergent Biosolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and immune-related therapeutics that assist the body's immune system to prevent or treat disease. The company develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious. Emergent Biosolutions manufactures and markets BioThrax, also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration (FDA) for the prevention of anthrax infection. The company also has product candidates in advanced stages of development and earlier stages of development.Manufacturing: Pharmaceuticals, prescription drugs.